<DOC>
	<DOCNO>NCT02590276</DOCNO>
	<brief_summary>The project focus C9orf72 , frequent genetic form frontotemporal dementia ( FTD , frontotemporal lobar degeneration , FTLD ) amyotrophic lateral sclerosis ( ALS ) . FTD second commonest cause degenerative dementia presenium Alzheimer 's disease . Behavioural cognitive impairment progressively lead dementia . ALS produce progressive muscle weakness lead death 2 4 year . Since 2006 , major discovery link FTLD ALS : 1 . TDP-43 aggregate neuron 2 . C9orf72 mutation major genetic cause disorder . Two major pathological subtypes define FTD , FTD-TDP FTD-TAU . C9orf72 mutation ( associate FTD-TDP ) frequent genetic cause FTD ( 15 % ) , FTD-ALS ( 65 % ) ALS ( 40 % ) . FTD difficult early stage ; clinical , biological imaging feature predict underlie pathology living patient . Therapeutic perspective emerge tau aggregation , progranulin deficit C9orf72 expansion ( antisense ) . Presymptomatic carrier genetic FTD would benefit , onset symptom , therapeutic would delay prevent disease . At step , become crucial develop marker know many year symptom , pathological progress begin , treat patient early stage disease . Markers also need predict pathology ( FTD-TDP/FTD-tau ) patient eligible trial target specific pathological lesion .</brief_summary>
	<brief_title>Predict Prevent Frontotemporal Lobar Degeneration ( FDT ) Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>This study investigate whether cognitive deficit , structural functional change detect symptom onset presymptomatic mutation carrier . The main objective project identify novel cognitive , brain imaging marker peripheral biomarkers early diagnosis FTLD , follow disease progression . Methodology 1 . Recruitment evaluation participant , neurological , behaviour cognition evaluation . One hundred participant include 20 C9orf72 patient 80 ' a-risk ' individual recruit evaluated clinical partner project ( Paris , Lille , Limoges , Rouen ) .. 'At-risk individual ' first degree relative C9ORF72 patient , high risk ( 50 % ) carry mutation . 2 . Identifying brain structural marker . Brain structural change evaluate voxel-based morphometry ( SPM12 software ) ass global brain atrophy evaluation atypical shape pattern cortical thickness ( Freesurfer software ) study cortical sulcus ( BrainVISA/Morphologist software ) . 3 . Identifying brain metabolic marker Fluoro Deoxy DGlucose-Positron Emission Tomography ( FDG-PET ) . We apply voxel-based method use Statistical Parametric Mapping software ( SPM8 ) compare different group analyze correlation brain metabolism cognitive deficit . 4 . Identifying peripheral biomarkers disease onset disease progression . We propose use RNA sequencing study gene expression RNA splice alteration lymphocytes C9ORF72 patient 'at risk individual ' .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Frontotemporal Lobar Degeneration</mesh_term>
	<criteria>Age ≥ 18 Signed inform consent genetic clinical study To carrier C9ORF72 mutation Diagnosis criterion FTD ALS To Frenchspeaking To affiliate social security scheme Absence another intercurrent neurological pathology ( vascular cerebral accident , tumor , etc ... .. ) Inclusion criterion asymptomatic relative Age ≥ 18 To first degree relative person carry C9ORF72 mutation OR first degree relative FTD ALS decease patient whose C9ORF72 mutation identify family Signed inform consent genetic clinical study To Frenchspeaking To affiliate social security scheme Absence proven neurologic disorder intercurrent neurological pathology ( vascular cerebral accident , tumor , etc ... .. ) Contraindication perform brain MRI ( wear pacemaker , cardiac valve incompatible vascular MRI surgical equipment , neurosurgery surgery vascular equipment , surgical equipment likely concentrate radio frequency field , intra ocular intra cerebral metal foreign body , claustrophobia , wear noncompliant radio intrauterine device ) , Inability lie one hour without move PETFDG contraindication Breastfeeding pregnant woman Human chorionic gonadotrophin ( BétâHCG ) positive determination Positive urine pregnancy test woman childbearing age Exclusion criterion relate asymptomatic : Clinical proven sign FTD , language disorder , praxis disorder , mnemic , parkinson 's syndrome amyotrophic lateral sclerosis . Counterindication perform brain MRI ( wear pacemaker , cardiac valve incompatible vascular MRI surgical equipment , neurosurgery surgery vascular equipment , surgical equipment likely concentrate radio frequency field , intra ocular intra cerebral metal foreign body , claustrophobia , wear noncompliant radio intrauterine device ) Severe chronic alcoholism PETFDG contreindication Inability lie one hour without move BétâHCG positive determination Positive urine pregnancy test woman childbearing age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>frontotemporal Dementia</keyword>
	<keyword>Amyotrophic lateral sclerosis</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>brain Imaging PET</keyword>
</DOC>